Beta-Amanitin – a potential payload for antibody drug conjugates (ADCs)

beta-Amanitin is an inhibitor of eukaryotic RNA polymerase II and RNA polymerase III, but not RNA polymerase I or bacterial RNA polymerase. It inhibits mammalian protein synthesis. These properties make it interesting as a new potential drug for ADC research. α-Amanitin is already known as effective payload for ADCs. beta-Amanitin has a comparable biological activity but in addition it has a carboxy group, suitable for coupling reactions.

ADC technology offers a wide potential for the future and Cfm Oskar Tropitzsch GmbH supplies besides beta-Amanitin many other payloads for antibody drug conjugation (ADC).

More news


Meet us in Milan

Our Head of Pharma, Michael Schaeffler, will be attending this year's CPhI and looks forward to meeting customers and partners in person.

Would you like to meet him at the event?...

Read more